The Defense Logistics Agency plans to issue a national requirements contract for Methylphenidate ER tablets (18 mg, 27 mg, 36 mg, and 54 mg in 100-count bottles). The acquisition will be unrestricted, fully competitive, and use a firm-fixed-price requirements contract with a one-year base plus four one-year options. The resulting national supply source will provide these items under FAR 52.216-21 to Department of War, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through DLA and VA prime vendor programs. This commercial item will be solicited under FAR Part 12, and the solicitation will be posted on DIBBS and SAM.gov. The projected solicitation date is September 2026, though DLA may issue it before or after that date; interested parties can contact Jeremy Brown at jeremy.brown@dla.mil or (445) 737-5419.

DLA plans to issue a solicitation for a national requirements contract for Methylphenidate ER tablets in 18 mg, 27 mg, 36 mg, and 54 mg strengths, 100-count bottles. The acquisition is unrestricted, fully competitive, and will result in a firm-fixed-price, requirements-type contract with a one-year base plus four one-year options. It will establish a national supply source for Department of War, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The product is a commercial item under FAR Part 12, with annual usage estimates provided in the solicitation’s Schedule of Supplies. The projected solicitation date is September 2026, subject to DLA issuing it earlier or later, and interested parties can monitor DIBBS/Sam.Gov and contact Jeremy Brown for questions.